Rozanolixizumab
Rozanolixizumab, sold as the brand name Rystiggo, is a monoclonal antibody medicine developed by UCB Pharma. It is a humanized/chimeric antibody that blocks the neonatal Fc receptor (FcRn). By blocking FcRn, it helps lower certain antibodies in the body, which can reduce autoimmune activity.
It is given by subcutaneous injection and is used to treat generalized myasthenia gravis (MG) in adults who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.
Common side effects include headache, infections, diarrhea, fever, hypersensitivity reactions, and nausea.
Regulatory history: Rozanolixizumab was approved for medical use in the United States in June 2023. In the European Union, a positive opinion was issued in November 2023, with approval in January 2024. The international nonproprietary name is Rozanolixizumab, and the product is marketed under the brand name Rystiggo.
This page was last edited on 3 February 2026, at 16:26 (CET).